Adding Dexamethasone to Continued Ranibizumab in Patients with Persistent DME

In this interview from ASRS 2018, Dr. Raj Maturi presents an update to Protocol U looking at the use of corticosteroid in combination with ranibizumab for patients with persistent diabetic macular edema (DME). From the original cohort, one-third of patients had intractable DME after 6 ranibizumab injections. For this analysis, total of 65 patients received dexamethasone and ranibizumab, while 64 had ranibizumab only. At 24 weeks, BCVA outcomes were similar in both groups, but the combination group had better anatomic outcomes than the ranibizumab-only group. Dr. Maturi cautions that patients who are on steroid therapy should be monitored closely for elevated IOP and cataract formation.

Relevant Financial Disclosures: Dr. Raj Maturi receives grant support from Genentech and Allergan.